In conclusion, we have shown that treatment with metyrapone diminishes hypercorticosteronemia without affecting atherosclerosis susceptibility in cholic acid-containing high cholesterol/high fat diet-fed LDL receptor knockout mice. The gene discussed is LDLR; the disease is atherosclerosis.